摘要:
Administration of certain 1-phenylalkanecarboxylic acid derivatives is useful for treating, preventing and/or reducing the risk of developing Alzheimer's Disease and multiple sclerosis.
摘要:
It is intended to provide a labeling precursor compound used for selectively producing radioactive halogen-substituted syn-1-amino-3-cyclobutane-carboxylic acids, and to provide a process for producing a radioactive halogen-substituted syn-1-amino-3-cyclobutane-carboxylic acid using the labeling precursor compound. A labeling precursor is used in which a phthalimide group is used as a protective group for protecting the amino group. The syn-form of the radioactive halogen-substituted 1-amino-3-cyclobutane-carboxylic acid can be selectively produced by labeling the labeling precursor with a radioactive halogen followed by deprotecting.
摘要:
A polyamic acid comprising at least 10 mol % repeating units represented by the formula [1] or [2]; and a polyimide represented by the formula [3] or [4] which is obtained from the polyamic acid. A polyimide film having high heat resistance and satisfactory in light-transmitting properties and tensile strength is obtained from the polyamic acid. (In the formulae, R1 and R2 each independently represents hydrogen or C1-10 alkyl; R3 and R4 each independently represents hydrogen, halogeno, C1-10alkyl, or phenyl or the R3 and R4 on adjoining carbon atoms are bonded to each other to form C3-8 cycloalkyl or phenyl; R5 represents a divalent organic group; and n is an integer of 2 or larger.)
摘要:
A process is provided for producing [18F]FACBC, which can reduce the production amount of impurities. Disclosed is a process for producing a radioactive fluorine-labeled organic compound, including a deesterification step of retaining, in a reverse-phase column, a compound represented by Formula (1): wherein R1 is a linear or branched C1-C10-alkyl chain or an aromatic substituent, and R2 is a protecting group; charging the column with an alkaline solution to deesterify the compound, and subsequently discharging the alkaline solution from the column to obtain a compound represented by Formula (2): wherein X is sodium or potassium; and a deprotection step of deprotecting the amino-protecting group of the compound obtained in the deesterification step to obtain a compound represented by Formula (3):
摘要:
The invention provides an industrial method for producing a spiroaminopyrrolidone derivative, which is an intermediate for producing a quinolone antibacterial agent.The invention provides a method for producing a compound represented by formula (2): (wherein n is an integer of 2 to 5; R1 represents a (substituted) alkyl group or a (substituted) aryl group; and R2 represents a (substituted) alkoxycarbonyl group, a (substituted) aralkyloxycarbonyl group, a (substituted) aliphatic acyl group, or a (substituted) aromatic acyl group), which includes treating a compound represented by formula (1): (wherein n, R1, and R2 are the same as defined above; and R3 represents a hydrogen atom, a (substituted) alkyl group, or a (substituted) aralkyl group) under a hydrogen gas atmosphere in the presence of a metallic catalyst.
摘要翻译:本发明提供一种生产螺环氨基吡咯烷酮衍生物的工业方法,其是用于生产喹诺酮抗菌剂的中间体。 本发明提供一种制备由式(2)表示的化合物的方法:(其中n为2至5的整数; R 1表示(取代的)烷基或(取代的)芳基; R 2表示(取代的) 烷氧基羰基,(取代的)芳烷氧基羰基,(取代的)脂族酰基或(取代的)芳族酰基),其包括处理由式(1)表示的化合物:其中n,R1和R2是 在氢气气氛下,在金属催化剂的存在下,R 3表示氢原子,(取代的)烷基或(取代的)芳烷基)。
摘要:
A carboxylic acid compound having cyclopropane ring(s) of the formula (I): wherein R is alkyl or alkenyl optionally having one or more 1,2-cyclopropylene in a carbon chain and/or optionally having cyclopropyl at the end of a chain,X is a single bond or alkylene, wherein the total number of carbon less the number of cyclopropane ring is 10-25, and a pharmaceutically acceptable salt thereof are provided. The compound (I) shows an LTP-like potentiation of synaptic transmission, allows slow metabolism in the living body, show a stable LTP-like potentiation of synaptic transmission, and is useful as an agent for LTP-like potentiation of synaptic transmission, a cognition-enhancing drug or an agent for the prophylaxis and treatment of dementia, a learning and memory disorder and a neurotransmitter release disorder.
摘要:
Optically active bisoxazoline compounds represented by the general formula (1), a process for producing the compounds, and a process for producing cyclopropanecarboxylic esters by using the same: wherein R1 and R2 are the same and each represents C1-6 alkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted phenyl or R1 and R2 are bonded each other together with the carbon atom of oxazoline ring to which they are bonded to form a ring; R3 is substituted or unsubstituted naphthyl; R4 and R5 are the same and each represent hydrogen or C1-6 alkyl, or R4 and R5 are bonded each other together with the carbon atom to which they are bonded to form a cycloalkyl ring having 3 to 6 carbon atoms; and * represents an asymmetric center.
摘要翻译:由通式(1)表示的光学活性的双恶唑啉化合物,该化合物的制备方法以及使用该化合物制备环丙烷羧酸酯的方法:其中R 1和R 2, SUP>相同,各自表示C 1-6烷基,取代或未取代的芳烷基或取代或未取代的苯基或R 1和R 2 O 2 >与它们所键合的恶唑啉环的碳原子一起形成环; R 3是取代或未取代的萘基; R 4和R 5是相同的,并且各自表示氢或C 1-6烷基,或R 4, R 5和它们所连接的碳原子一起形成具有3〜6个碳原子的环烷基环; *表示非对称中心。
摘要:
A process for the production of a 3,3-dimethyl-2-formylcyclopropanecarboxylic acid derivative of formula (2): wherein R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl, which process comprises reacting a 3,3-dimethyl-2-(2-methyl-1-propenyl)cyclopropanecarboxylic acid compound of formula (1): wherein R is as defined above, with a periodic acid compound in the presence of a ruthenium compound.
摘要:
The invention is a novel series of cyclic amino acids which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included.